Search results for "Static"

showing 10 items of 1528 documents

Cell-Free Circulating Plasma hTERT mRNA Is a Useful Marker for Prostate Cancer Diagnosis and Is Associated with Poor Prognosis Tumor Characteristics

2012

BackgroundSerum prostate-specific antigen (PSA) is the most widely used marker for diagnosing prostate cancer (PCa). It lacks specificity and predictive value, resulting in inaccurate diagnoses and overtreatment of the disease. The aim of this study was to assess the usefulness of plasma telomerase reverse transcriptase (hTERT) mRNA as a diagnostic and prognostic tool for PCa and its association with clinicopathological parameters of tumors.Principal findingsPlasma hTERT mRNA levels were determined by qRT-PCR in 105 consecutive patients with elevated PSA levels and in 68 healthy volunteers. The diagnostic accuracy, the efficacy as a prognostic factor of biochemical recurrence and the associ…

MaleBiochemical recurrenceOncologymedicine.medical_specialtyPathologyUrologyScienceProstate cancerDiagnostic MedicineInternal medicineBlood plasmaBiopsyBiomarkers TumorPathologyCancer Detection and DiagnosisEarly DetectionHumansMedicineTelomerase reverse transcriptaseRNA MessengerTelomeraseAgedBenign Prostatic HyperplasiaTumor markerAged 80 and overClinical ChemistryUnivariate analysisMultidisciplinarymedicine.diagnostic_testbusiness.industryProstate CancerQProstate DiseasesRProstatic NeoplasmsMiddle AgedPrognosismedicine.diseaseClinical Laboratory SciencesOncologyMedicineBiomarker (medicine)businessBiomarkersCancer ScreeningResearch ArticleGeneral PathologyPLoS ONE
researchProduct

Balancing Passive and Active Targeting to Different Tumor Compartments Using Riboflavin-Functionalized Polymeric Nanocarriers

2017

Riboflavin transporters (RFTs) and the riboflavin carrier protein (RCP) are highly upregulated in many tumor cells, tumor stem cells, and tumor neovasculature, which makes them attractive targets for nanomedicines. Addressing cells in different tumor compartments requires drug carriers, which are not only able to accumulate via the EPR effect but also to extravasate, target specific cell populations, and get internalized by cells. Reasoning that antibodies are among the most efficient targeting systems developed by nature, we consider their size (-10-15 nm) to be ideal for balancing passive and active tumor targeting. Therefore, small, short-circulating (10 kDa, -7 nm, t1/2 - 1 h) and large…

MaleBiodistributionMaterials scienceCell SurvivalPolymersSurface PropertiesRiboflavinBioengineering02 engineering and technology010402 general chemistry01 natural sciencesPolyethylene GlycolsMiceProstate cancerDownregulation and upregulationRiboflavin-carrier proteinCell Line TumorPEG ratiomedicineAnimalsHumansTissue DistributionGeneral Materials ScienceParticle Sizepassive and active tumor targetingCell ProliferationDrug CarriersbiologyMechanical EngineeringMembrane Transport ProteinsProstatic NeoplasmsTransporterGeneral Chemistry021001 nanoscience & nanotechnologyCondensed Matter Physicsmedicine.diseasen/a OA procedure0104 chemical sciencesCell biologybranched PEGBiochemistrybiology.proteinHeterograftsAntibody0210 nano-technologyDrug carrierNano Letters
researchProduct

HPMA-LMA copolymer drug carriers in oncology: an in vivo PET study to assess the tumor line-specific polymer uptake and body distribution.

2013

Polymeric drug carriers aim to selectively target tumors in combination with protecting normal tissue. In this regard polymer structure and molecular weight are key factors considering organ distribution and tumor accumulation of the polymeric drug delivery system. Four different HPMA based copolymer structures (random as well as block copolymers with lauryl methacrylate as hydrophobic block) varying in molecular weight, size and resulting architecture were analyzed in two different tumor models (AT1 prostate carcinoma and Walker-256 mammary carcinoma) in vivo. Polymers were labeled with (18)F and organ/tumor uptake was followed by μPET imaging and ex vivo biodistribution. Vascular permeabi…

MaleBiodistributionPolymers and PlasticsBioengineeringVascular permeabilityBiomaterialschemistry.chemical_compoundPolymethacrylic AcidsIn vivoPolymer chemistryMaterials ChemistryDistribution (pharmacology)AnimalsTissue DistributionWhole Body ImagingCarcinoma 256 WalkerParticle SizeChemistryProstatic NeoplasmsIn vitroRatsDextranPositron-Emission TomographyBiophysicsMethacrylatesNanoparticlesRadiopharmaceuticalsDrug carrierEx vivoNeoplasm TransplantationBiomacromolecules
researchProduct

44Sc-DOTA-BN[2-14]NH2 in comparison to 68Ga-DOTA-BN[2-14]NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET?

2011

In the present study we demonstrate the in vitro and in vivo comparison of the (44)Sc and (68)Ga labeled DOTA-BN[2-14]NH(2). (44)Sc is a positron emitter with a half life of 3.92 h. Hence it could be used for PET imaging with ligands requiring longer observation time than in the case of (68)Ga.The binding affinity of (nat)Sc-DOTA-BN[2-14]NH(2) and (nat)Ga-DOTA-BN[2-14]NH(2) to GRP receptors was studied in competition to [(125)I-Tyr(4)]-Bombesin in the human prostate cancer cell line PC-3. A preliminary biodistribution in normal rats was performed, while first microPET images were assessed in male Copenhagen rats bearing the androgen-independent Dunning R-3327-AT-1 prostate cancer tumor.The …

MaleBiodistributionmedia_common.quotation_subjectGallium Radioisotopeschemistry.chemical_compoundHeterocyclic Compounds 1-RingIn vivoProstateCell Line TumormedicineDOTAAnimalsHumansTissue DistributionInternalizationReceptorneoplasmsmedia_commonRadioisotopesRadiationChemistrybusiness.industryHalf-lifeProstatic NeoplasmsMolecular biologyRatsmedicine.anatomical_structureIsotopes of galliumGastrin-Releasing PeptidePositron-Emission TomographyBombesinRadiopharmaceuticalsNuclear medicinebusinessScandiumApplied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
researchProduct

Inferring postimplant dose distribution of salvage permanent prostate implant (PPI) after primary PPI on CT images

2018

International audience; PURPOSE:To evaluate the dose distribution of additional radioactive seeds implanted during salvage permanent prostate implant (sPPI) after a primary permanent prostate implant (pPPI).METHODS AND MATERIALS:Patients with localized prostate cancer were primarily implanted with iodine-125 seeds and had a dosimetric assessment based on day 30 postimplant CT (CT1). After an average of 6 years, these patients underwent sPPI followed by the same CT-based evaluation of dosimetry (CT2). Radioactive seeds on each CT were detected. The detected primary seeds on CT1 and CT2 were registered and then removed from CT2 referred as a modified CT2 (mCT2). Dosimetry evaluations (D90 and…

MaleBrachytherapy[SDV.CAN]Life Sciences [q-bio]/CancerDose distribution[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology030218 nuclear medicine & medical imagingIodine Radioisotopes03 medical and health sciencesProstate cancer0302 clinical medicineProstateDosimetryIodine seedsmedicineHumansDosimetryRadiology Nuclear Medicine and imagingRadiometrySalvage TherapyPrimary permanentSalvage brachytherapyProstate cancerbusiness.industryProstateProstatic NeoplasmsProstate implantRadiotherapy Dosagemedicine.disease3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisTomography X-Ray ComputedbusinessNuclear medicineSalvage brachytherapy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Ileal Melanoma, A Rare Cause of Small Bowel Obstruction: Report of a Case, and Short Literature Review.

2020

Background: Malignant melanoma frequently spreads to the gastrointestinal tract, with 60% of patients with advanced metastatic disease showing digestive involvement; however, primary MM of the small intestine is a controversial diagnosis. In fact, whether these lesions arise as true small bowel primary neoplasms or represent metastases from unidentified cutaneous melanomas remains debatable. The most common complications are intestinal obstruction, massive gastrointestinal bleeding, and perforation. Objective & Methods: We report a case of a 64-year-old patient, with an unremarkable medical history, in which a late diagnosis of primary ileal malignant melanoma in the setting of an emer…

MaleCT scanmedicine.medical_specialtyGastrointestinal bleedingmedicine.medical_treatmentPerforation (oil well)Metastasis03 medical and health sciences0302 clinical medicineIleumLaparotomymedicineHumansRadiology Nuclear Medicine and imagingMedical historymetastatic disease.Ileal MelanomaSmall Bowel ObstructionAntineoplastic Agents AlkylatingMelanomaPharmacologyGastrointestinal tractCurrent Radiopharmaceuticalsbusiness.industryGeneral surgeryMelanomaMiddle Agedmedicine.diseaseBowel obstructionDacarbazineIleal NeoplasmsSettore MED/18 - Chirurgia GeneralePEThypercaptation030220 oncology & carcinogenesisPositron-Emission Tomography030211 gastroenterology & hepatologybusinessmetastatic diseaseIntestinal ObstructionCurrent radiopharmaceuticals
researchProduct

Twelve Months of Time-restricted Eating and Resistance Training Improves Inflammatory Markers and Cardiometabolic Risk Factors.

2021

Introduction Recently, a modified intermittent fasting protocol was demonstrated to be able to maintain muscle mass and strength, decrease fat mass, and improve some inflammation and cardiovascular risk factors in healthy resistance-trained males after 2 months. The present study sought to investigate the long-term effects on these parameters. Methods The experiment was a single-blind randomized study. Twenty healthy subjects were enrolled and underwent 12 months of either a time-restricted eating (TRE) diet or a normal diet (ND) protocol, along with resistance training. In the TRE protocol, subjects consumed their energy needs in three meals during an 8-h period of time each day (1 pm, 4 p…

MaleCalorieNormal dietmedicine.medical_treatmentPhysiologyPhysical Therapy Sports Therapy and RehabilitationBody Mass Indexchemistry.chemical_compoundInsulin resistanceIntermittent fastingmedicineHumansOrthopedics and Sports MedicineSingle-Blind MethodInsulin-Like Growth Factor IAdipositymedicine.diagnostic_testCholesterolbusiness.industryInsulinCardiometabolic Risk FactorsResistance TrainingFastingmedicine.diseasechemistryHomeostatic model assessmentInsulin ResistanceLipid profilebusinessEnergy IntakeMedicine and science in sports and exercise
researchProduct

Chronic administration of green tea extract to TRAMP mice induces the collapse of Golgi apparatus in prostate secretory cells and results in alterati…

2011

Considering its long latency, prostate cancer (PCa) represents an ideal target for chemoprevention strategies. Green tea extract (GTE) has been proved to be one of the most promising natural substances capable of inhibiting PCa progression in animal models (transgenic adenocarcinoma of mouse prostate), as well as in humans. However, the cellular targets of the GTE action are mostly unknown. The main objective of this work was to investigate whether the endoplasmic reticulum (ER) and the Golgi apparatus (GA), known to be actively involved in sensing stress stimuli and initiating and propagating cell death signalling, may represent the subcellular targets of GTE action. To this end, 42 TRAMP …

MaleCancer ResearchCellGolgi ApparatusMice TransgenicGreen tea extractAdenocarcinomaEndoplasmic ReticulumCatechinsymbols.namesakeMicegreen tea extract; chemoprevention; prostate cancer; clusterin; ultrastructure; transgenic adenocarcinoma of mouse prostate.medicineAnimalsClusterinbiologyTeaEndoplasmic reticulumProstatic NeoplasmsCell cycleGolgi apparatusCell biologyMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureClusterinOncologyApoptosisgreen tea extract chemoprevention prostate cancer clusterin ultrastructure transgenic adenocarcinoma of mouse prostatesymbolsbiology.proteinProtein Processing Post-TranslationalTrampInternational journal of oncology
researchProduct

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

2015

BACKGROUND: The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. METHODS: Patients with KRAS mutant mCRC were treated in the second-line setting with FOLFIRI (5-fluorouracil/folinic acid/irinotecan) plus pimasertib. The primary objective of the safety run-in phase was to determine the maximum-tolerated dose (MTD) and the recommended phase II dose of pimasertib combined with FOLFIRI. RESULTS: Sixteen patients were enrolled in the trial. Ten and six patients were treated daily with 45 and 60 …

MaleCancer ResearchColorectal cancermedicine.medical_treatmentLeucovorinColorectal NeoplasmPharmacologymedicine.disease_causepimasertibcombination therapyAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Metastasiscombination therapy second-line treatmentAged 80 and overProto-Oncogene ProteinCetuximabKRAS-mutated metastatic colorectal cancerMedicine (all)MEK inhibitorMiddle AgedNeoplasm MetastasiTreatment OutcomeOncologyFluorouracilFOLFIRISecond-line treatmentFemaleFluorouracilKRASColorectal NeoplasmsPimasertibHumanmedicine.drugNiacinamideProto-Oncogene Proteins p21(ras)FOLFIRIProto-Oncogene ProteinsmedicineHumansCombination therapyneoplasmsAgedChemotherapyMEK inhibitorAntineoplastic Combined Chemotherapy Protocolbusiness.industryKRAS -mutated metastatic colorectal cancerGenes raras Proteinmedicine.diseasedigestive system diseasesGenes rassecond-line treatmentMutationras ProteinsClinical StudyCancer researchCamptothecinHuman medicinebusinessCamptothecinThe British journal of cancer
researchProduct

Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen

2019

<b><i>Background:</i></b> Vinflunine is a microtubule inhibitor of the vinca alkaloid class approved for the treatment of urothelial bladder carcinoma after a platinum-containing regimen. <b><i>Methods:</i></b> To evaluate the effectiveness of vinflunine, we enrolled 80 subjects with a histologically confirmed diagnosis of metastatic urothelial bladder carcinoma that had previously undergone chemotherapy with a platinum-containing regimen and had measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST). The patients (<i>n</i> = 80) received vinflunine (Javlor®) every 3 weeks at 320 mg/m<sup>2&…

MaleCancer ResearchJavlor®medicine.medical_treatmentMetastasichemistry.chemical_compound0302 clinical medicineRetrospective StudieAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicineNeoplasm MetastasisAged 80 and overVinflunineGeneral MedicineMiddle AgedTolerabilityNeoplasm MetastasiOncologyTolerabilityResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisUrinary Bladder NeoplasmUrothelial carcinomaFemaleHumanmedicine.medical_specialtyMetastatic Urothelial Carcinomamedicine.drug_classBladderUrologyPainVinblastineVinca alkaloid03 medical and health sciencesCarcinomamedicineHumansChemotherapyRetrospective StudiesAgedChemotherapyAntineoplastic Combined Chemotherapy ProtocolToxicitybusiness.industrymedicine.diseaseRegimenUrinary Bladder NeoplasmschemistryCisplatinbusiness
researchProduct